By Fineline Cube 
China-based Shanghai Bio-heart Biological Technology Co., Ltd (HKG: 2185) hosted the product launch of its multipole renal arterial radiofrequency ablation system, Iberis, during the 19th Oriental Congress of Cardiology (OCC 2025). The event highlighted the system’s unique capabilities and smooth procedural outcomes.
Live Case Demonstration
A live case demonstration of a transradial access (TRA) renal denervation (RDN) procedure was successfully broadcast during the conference, completing the surgery without complications. This showcased the Iberis system’s clinical effectiveness and safety.
Global Approval and Commercialization
To date, Iberis remains the only RDN product globally approved for both transradial and transfemoral access. The commercialization of the product in China will be jointly carried out by Kenover Medical Technology, a subsidiary of Grand Pharmaceutical Group Co., Ltd. (HKG: 0512).-Fineline Info & Tech